BIOLASE Inc. (NASDAQ:BIOL) is up 35% in a month. The company and Dr. L. Stephen Buchanan have announced a clinical advisory partnership to expand the adoption of lasers and enhanced hands-on training services with a leading endodontics player.
Buchanan has over 30 years of experience in teaching endodontic courses in dental schools and symposiums worldwide and at his ultramodern training facility DELabs in Santa Barbara, California. In addition, he is a faculty member at the University of Pacific’s Arthur ADugoni School of Dentistry and maintains limited endodontics practice in Santa Barbara.
Buchanan said BIOLASE enhances the endodontic standard of care through the Er,Cr:YSGG Waterhouse device. He explained that technology backs singed RCT visits with minimal invasive endodontic procedures since it cavitates sodium hypochlorite effectively in minor preparations. Also, BIOLASE CEO John Beaver stated that they are proud to partner with Buchanan given his expertise in R&D on new instruments, techniques, and technology in endodontics. With this partnership, BIOL is worth watching in months to come.
On Tuesday, BIOL stock fell 1.27% at $0.7675 with more than 2.73 million shares, compared to its average volume of 4.62 million shares. The stock has moved within a range of $0.7614 – 0.8150 after opening the trade at $0.7906.